Rapid growth in the geriatric population, rising prevalence of eye diseases, limited number of ophthalmologists, government initiatives to encourage the adoption of EHR/EMR, and the increasing adoption of teleophthalmology are the factors driving the growth of the ophthalmology PACS market.
The global ophthalmology PACS market is projected to reach USD 160.2 million by 2023 from an estimated USD 106.6 million in 2018, at a CAGR of 8.5% during the forecast period. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=130879968 Based on type, the ophthalmology PACS market is segmented into standalone and integrated PACS. Among these, the integrated PACS segment is expected to command the largest share of the ophthalmology PACS market in 2018. The advantages associated with the use of integrated PACS, such as ease of deployment and use, easy interoperability, data security, portability, and cost-effectiveness are driving the growth of this segment. Based on delivery model, the ophthalmology PACS market is segmented into on-premise and web/cloud-based models. The web/cloud-based PACS segment is expected to grow at the highest CAGR during the forecast period. The high growth rate can be attributed to the fact that, these models do not require any significant setup charges. Maintenance and support service charges are also included in subscription fees, which make these delivery models more affordable for customers. Based on end user, the ophthalmology PACS market is segmented into hospitals, specialty clinics & ambulatory surgery centers, and other end users. In 2018, the specialty clinics & ambulatory surgical centers segment is expected to command the largest share of the ophthalmology PACS market. In 2018, North America is expected to command the largest share of the market. With the growing aging population and increasing incidence of age-related eye diseases. Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=130879968 The ophthalmology PACS market is marked by the presence of several big and small players. Prominent players in this market include Carl Zeiss Meditec AG (Germany), Topcon Corporation (Japan), Heidelberg Engineering (Germany), Sonomed Escalon (US), Visbion (UK), EyePACS (US), and IBM Corporation (Merge Healthcare) (US).
0 Comments
Hematology Analyzers and Reagents Market statistics and research analysis released in latest report8/18/2020 The increasing incidence of blood disorders and the growth in blood donation are the major factors driving the growth of the global hematology products market. Furthermore, factors such as technological advancements in hematology analyzers and reagents and integration of flow cytometry techniques with hematology analyzers are expected to support the growth of this market during the forecast period.
The report "Hematology Analyzers and Reagents Market by Products & Services (Hematology Analyzers (5 Parts, 6 Parts, 3 Part, PoC, Semi-Automated), Hemostasis, Immunohematology), Price Range (High, Low), End User (Government labs) - Global Forecast to 2023" Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153222146 On the basis of products & services, the hematology analyzers and reagents market is classified into hematology, hemostasis, and immunohematology products and services. The hematology products and services segment is projected to grow at the highest growth rate during the forecast period. Factors such as the increasing adoption of POC testing hematology analyzers in emerging economies, launch of technologically advanced hematology products coupled with the increasing preference towards automation, the growing trend of the ‘reagent rental’ business model, and the rising availability of a wide range of services from major hematology providers, are driving the growth of this segment. By end user, the hematology products and services market is segmented into hospital laboratories, commercial service providers, government reference laboratories, and research & academic institutes. North America is estimated to account for the largest share of the market in 2018. This can be attributed to the rising incidence of patients suffering from blood disorders, growing prevalence of target diseases, and the rising demand for blood transfusions increasing the demand for hematology testing in the region. Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=153222146 The major players of the global hematology analyzers and reagents market are Sysmex (Japan), Danaher (US), Nihon Kohden (Japan), Siemens (Germany), Abbott Laboratories (US), Boule Diagnostics (Sweden), HORIBA (Japan), Bio-Rad Laboratories (US), BioSystems (Spain), Diatron (Hungary), Drew Scientific (US), EKF Diagnostics (UK), Mindray (China), Ortho Clinical Diagnostics (US), and Roche (Switzerland). Factors such as the improving quality of healthcare, improvements in healthcare systems, the growing medical tourism market in Asian countries, and increasing government initiatives are the key factors driving the growth of this market. The benefits of CRM software and a growing focus on patient engagement are the major factors driving the growth of the healthcare CRM market.
The report Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast period. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88873203 Based on end user, the healthcare CRM market is segmented into healthcare providers, the life sciences industry, and healthcare payers. The healthcare providers segment is estimated to account for the largest share of the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions. On the basis of component, the healthcare CRM market is segmented into software and services. The services segment is expected to dominate the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Services form a large component of the healthcare CRM market primarily due to the indispensable role of service providers when it comes to the use of CRM solutions for healthcare. Geographically, the global healthcare CRM market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to hold the largest share of the healthcare CRM market. Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=88873203 The key players in the healthcare CRM market are Salesforce.com, Inc. (US), SAP SE (Germany), Oracle (US), Microsoft (US), IBM (US), Influence Health (US), SugarCRM (US), Accenture (Ireland), Healthgrades (US), and Infor, Inc. (US). The major factors driving the growth of this market are the rising need to curtail healthcare costs and the increasing patient volume due to the rising prevalence of chronic diseases. In addition, the government initiatives for HCIT adoption and the advantages of clinical workflow solutions in enhancing patient care and safety are also boosting the market growth.
The Clinical Workflow Solutions Market is expected to reach USD 12.1 billion by 2023 from an estimated USD 6.8 billion in 2018, at a CAGR of 12.4%. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=146901412 Based on products, the clinical workflow solutions market is segmented into workflow automation solutions, care collaboration solutions, real-time communication solutions, data integration solutions, and enterprise reporting and analytics solutions. The data integration segment is estimated to account for the largest market share in 2018. The large share of this segment can be attributed to the growing requirement for a proper management and storage solution that can manage the increasing volume of medical records. Also the government incentives, penalties, and the necessity to cut costs are contributing towards the market growth. Based on end users, the clinical workflow solutions market is segmented into hospitals, long-term care facilities, and ambulatory care facilities. The hospital segment is estimated to account for the largest market share in 2018. This is because increasing number of initiatives to improve the quality of care delivered to patients and the growing need to improve profitability of healthcare operations and curtail healthcare costs. North America is expected to account for the largest share of the clinical workflow solutions market in 2018, followed by Europe. The dominance of the North American region can be attributed to the growing healthcare IT spending, developed infrastructure, evolving regulations for better healthcare outcomes, and the presence of major market players in the region. Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=146901412 The prominent players in the clinical workflow solutions market are are Hill-Rom Holdings, Inc. (US), Ascom Holding AG (Switzerland), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Cisco Systems, Inc. (US), Stanley Black & Decker, Inc. (US), Cerner Corporation (US), Infor, Inc. (US), Allscripts Healthcare Solutions, Inc. (US), and McKesson Corporation (US). Growth in the infusion pump software market is mainly driven by factors such as the increasing incidence of chronic diseases, along with rapid growth in the geriatric population, growing number of surgical procedures performed, rising demand for ambulatory and home care infusion pumps, and technological developments.
The global Infusion Pump Software Market is expected to reach USD 1,044 million by 2024 from USD 742 million in 2019, at a CAGR of 7.1%. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=126400367 On the basis of type, the infusion pump software market is segmented into Dose error reduction software (DERS), clinical workflow software, interoperability software and other software. The DERS segment held the largest share of the infusion pump software market in 2018 and this segment is also projected to register the highest growth during the forecast period. Increasing number of medication errors using infusion pumps is a major factor driving market growth. The various automated safety features offered by this software also supporting the adoption of DERS in infusion pumps. On the basis of indication, the market is segmented into general infusion, pain & anesthesia management, insulin infusion, chemotherapy, enteral infusion, and others. The general infusion segment commanded the largest share of the market in 2018. However, the insulin infusion market is projected to register the highest CAGR owing to a significant increase in the prevalence of diabetes worldwide and the pump’s ease of use for prolonged insulin infusion. Geographically, North America is expected to dominate the global infusion pump software market in 2018, while the Asia Pacific region is expected to register the highest CAGR during the forecast period. Speak To Analyst: -https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=126400367 The major players operating in the infusion pump software market include BD (US), B. Braun (Germany), Baxter (US), ICU Medical (US), and Terumo Medical (Japan). Other players involved in this market include Fresenius Kabi (Germany), Moog (US), F. Hoffmann-La Roche (Switzerland), Ypsomed (Switzerland), Medtronic (Ireland), Smiths Medical (US), and Micrel Medical Devices (Greece). Microtomes operate on different technologies, including manual, semi-automated, and fully automated. Manual microtomes segment accounted for the largest market share in 2018. Manual microtomes are cost-effective and are easier to use as compared to automatic and semi-automatic modules. These factors are supporting their adoption in the market, and the trend is anticipated to continue over the forecast period.
The report Microtome Market is expected to grow from USD 129 million in 2019 to reach USD 177 million by 2024, at a CAGR of 6.5%. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=230495411 Clinical laboratories and hospital laboratories are the main end-users of microtomes, among others. In 2018, the hospital laboratories segment accounted for the largest market share and was expected to grow at the highest CAGR during the forecast period. The large share of the hospital laboratories segment is attributed to the increasing number of patient visits to hospitals, rising number of in-house clinical diagnostic procedures performed in hospitals, growing awareness regarding early diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals. By region, the microtomes market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest market share, followed by Europe. Read More: -https://www.marketsandmarkets.com/PressReleases/microtomes.asp The prominent players operating in the microtomes market include Thermo Fisher Scientific (US), Danaher Corporation (US), Sakura Finetek (Japan), SLEE Medical GmbH (Germany), MEDITE GmbH (Germany), Histo-Line Laboratories (Italy), Amos Scientific (Australia), RMC Boeckeler (US), Diapath S.p.A. (Italy), and Jinhua YIDI Medical Appliance (China). Animal Growth Promoters and Performance Enhancers Market: Emerging Trends and Global Future Forecast8/10/2020 The growth of this market is primarily driven by the increasing global meat demand, research into alternatives to antibiotics, and the need to deal with epidemics and environmental factors. However, various countries have stringent regulations in place against antibiotics and particular growth promoters, which has affected their adoption.
The report Animal Growth Promoters and Performance Enhancers Market is projected to reach USD 18.5 billion by 2024 from an estimated USD 13.9 billion in 2019, at a CAGR of 5.9% during the forecast period. Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137134167 Based on type, the animal growth promoters and performance enhancers market is segmented into antibiotic and non-antibiotic growth promoters. The non-antibiotic growth promoters segment accounted for the largest share of the animal growth promoters and performance enhancers market in 2018. The large share of this segment can be attributed to their economic benefits, the wide range of substances with applications in different production animals, environmental sustainability, and the increasing number of regulations on antibiotics and hormones. On the basis of animal type, the animal growth promoters and performance enhancers market is segmented into poultry, swine, livestock, aquaculture, and other farm animals (equine, rabbit, camel, deer, yak, and geese). In 2019, the poultry segment accounted for the largest share of the animal growth promoters and performance enhancers market. In 2019, the Asia Pacific region accounted for the largest market share of 36.7%, followed by North America (26.1%) in 2018. The largest share of the Asia Pacific region is attributed to the strong animal products industry in this region, Read more: - https://www.marketsandmarkets.com/PressReleases/animal-growth-promoters-performance-enhancers.asp The key players in the global animal growth promoters and performance enhancers market are Merck and Co. Inc. (US), Cargill Inc. (US), Royal DSM N.V. (Germany), Vetoquinol (France), Bupo Animal Health (SA), Elanco Animal Health Inc. (US), CHR Hansen (UK), Novus International Inc. (US), BASF SE (UK), Lallemond Inc. (Canada), Bluestar Adisseo Company (France), Evonik Industries AG (UK), and Land O Lake Inc.(US). The rising incidences of chronic and infectious diseases, increasing awareness of health and fitness, as well as major technological advancements are key factors driving the IVD market in the U.S. However, the lack of sufficient budget and reimbursement for novel diagnostic tests are restraining market growth.
The U.S. In Vitro Diagnostics (IVD) Market is projected to reach USD 25.99 Billion in 2020 at a CAGR of 4.7% from 2015 to 2020. Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66290979 The U.S. IVD product & services market is broadly segmented into reagents, instruments, services, and data management software. The reagents segment accounted for the largest share of the U.S. IVD product & service market in 2014, and is expected to grow at a highest CAGR during the forecast period. The large share of this segment is primarily attributed to the accessibility of a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders at early stages. On the basis of end user, the U.S. IVD market is segmented into hospital laboratories, clinical/independent laboratories, and others. In 2014, the hospital laboratories segment accounted for the largest share of the U.S. IVD market in the U.S. The high inpatient flow and ancillary outpatient flow in hospitals, increasing prevalence of chronic and infectious diseases, and growing number of accredited laboratories are key factors driving market growth in this end-user segment. The U.S. IVD market has been segmented into four regions namely, South, Midwest, Northeast, and West. In 2014, the South region commanded the largest share of the U.S. IVD market, followed by West. Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=66290979 Some major players in the U.S. IVD market are Roche Diagnostics Limited (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickson and Company (U.S.), Johnson & Johnson (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Siemens Healthcare (Germany), Bio-Rad Laboratories, Inc. (U.S.), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Alere Inc. (U.S.), Ortho-Clinical Diagnostics Inc. (U.S.), and bioMérieux (France). Factors such as rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements are driving the growth of this market.
The North American Drug Delivery Technologies Market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5%. Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1209 In this report, the North American drug delivery technologies market is segmented on the basis of route of administration, end user, and region. Based on route of administration, the North American drug delivery technologies market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery market is expected to grow at the highest CAGR during the forecast period. The high growth in this segment is attributed to the advantages of topical drugs, such as convenience and ease of use, painless application of the correct dosage at the affected site, noninvasive nature, superior spreadability, and enhanced patient compliance. The North American drug delivery technologies market is divided into two country-level segments, namely, the U.S. and Canada. The U.S. is expected to continue to dominate the market during the forecast period. The large share of the U.S. in the North American market can primarily be attributed to factors such as the rising prevalence of chronic diseases; rapid growth in the geriatric population; growth in the biologics market; and increasing number of regulatory approvals, new product launches, and technological advancements. Based on end user, the market is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, home care settings, and other end users. The home care settings segment is expected to register the highest CAGR during the forecast period. Read More: - https://www.marketsandmarkets.com/PressReleases/north-american-drug-delivery-technologies.asp The North American drug delivery technologies market is a highly competitive market with the presence of several big and emerging players. Moreover, each product segment has a different set of vendors. Johnson & Johnson, Inc. (U.S.), Novartis AG (Switzerland), F. Hoffman-La-Roche Ltd. (Switzerland), Bayer AG (Germany), Pfizer, Inc. (U.S.), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), Merck & Co, Inc. (U.S.), Sanofi (France), Antares Pharma, Inc. (U.S.), and GlaxoSmithKline Plc. (U.K.) are some of the prominent players in the North American drug delivery technologies market. The report Cardiac Marker Testing Market analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
This report studies the global Cardiac Marker Testing Market over the forecast period of 2016 to 2021. The market is expected to reach ~USD 3.50 Billion by 2021, at a CAGR of 8.8% from 2016 to 2021. Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64885447 A number of factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are fueling the growth of the cardiac marker testing market. Based on type, the global cardiac marker testing market is divided into six segments, namely, troponin I and T, CK-MB, BNP or NT-proBNP, Myoglobin, hsCRP, and other biomarkers. The other biomarkers segment includes galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine. On the basis of product, the global cardiac marker testing market is segmented into reagents and kits and instruments. The instruments section is further segmented on the basis of method, namely, chemiluminescence, immunofluorescence, ELISA, and immunochromatography. On the basis of disease, the cardiac marker testing market is segmented into myocardial infarction and congestive heart failure. On the basis of type of testing, the cardiac marker testing market is segmented into laboratory testing and point-of-care testing. As of 2016, North America held the largest share of the global cardiac marker testing market, followed by Europe. However, the Asia-Pacific market is expected to register the highest CAGR of 11.7% from 2016 to 2021. Read more: - https://www.marketsandmarkets.com/PressReleases/cardiac-marker-testing.asp Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation, Japan), Ortho Clinical Diagnostics (a subsidiary of The Carlyle Group, U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) (China) are some of the key players operating in the global cardiac marker testing market. |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |